pcsk-9

Bococizumab(PF-04950615) is a humanized mAb against PCSK9 and an inhibitor of the synthesis of PCSK9 in the liver that reduces the amount of low-density lipoprotein cholesterol (LDL-C) in the blood.Bococizumab is used to treat hypercholesterolemia.

Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.

Evolocumab is an inhibitor of the humanized monoclonal antibody PCSK9. It binds to circulating PCSK9 protein, resulting in inhibition of PCSK9 binding to LDLR. It can be used in studies of hypercholesterolemia and atherosclerotic cardiovascular disease.

Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody to Subtilisin/Kexin Protein Converting Enzyme Type 9 (PCSK9) that binds to the catalytic domain of PCSK9 and lowers low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia.Frovocimab is used in the study of hypercholesterolemia. Frovocimab is used to study hypercholesterolemia.

Lodelcizumab (LGT 209) is a monoclonal antibody targeting the preprotein convertase Bacillus subtilis protease Kexin-9 (PCSK9) and is used to study hypercholesterolemia.

RG-7652 is a humanized monoclonal antibody targeting PCSK9 for the study of cardiovascular disease.

Anti-PCSK9 Antibody is a CHO-expressed human antibody targeting PCSK9. It features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Tafolecimab (IBI-306) is a humanised monoclonal antibody targeting PCSK9, capable of improving multiple lipid parameters (LDL, LDL-C, LDL-CFB, etc.), suitable for studying hypercholesterolaemia and mixed hyperlipidaemia.